Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

In prostate cancer, hormone therapy is treatment to keep the cancer cells from getting testosterone, the main male hormone (androgen). Hormone therapy for prostate cancer is also called ...

Analysis of data from a large patient population revealed a lower survival rate for men with prostate cancer (PCa) and depression compared with those without depression as well as healthy controls, ...

The novel MEK inhibitor atebimetinib in combination with modified gemcitabine/nab-paclitaxel led to a 12-month overall ...

If you have prostate cancer, your health care provider may have told you about a medicine called Nubeqa (darolutamide). The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer ...

Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...

Dr. Matthew Smith answers the question: 'Hormone Refractory Prostate Cancer?' March 16, 2009 -- Question: What is hormone refractory prostate cancer? Answer: Nearly all men respond to initial ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

Joe Biden’s recent diagnosis of "aggressive" prostate cancer has sparked concerns about how far the disease has advanced. The former president’s prostate cancer has been characterized by a Gleason ...

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...

A former prostate cancer patient who got the all-clear said taking part in a trial that cut his radiotherapy treatments ...